WKQ-0014730
英文名稱：L-α-Glutamyl-L-alanyl-L-alanylglycyl-L-isoleucylglycyl-L-isoleucyl-L-leucyl-L-threonyl-L-valine
英文別名：L-Valine, N-[N-[N-[N-[N-[N-[N-[N-(N-L-α-glutamyl-L-alanyl)-L-alanyl]glycyl]-L-isoleucyl]glycyl]-L-isoleucyl]-L-leucyl]-L-threonyl]-;L-α-Glutamyl-L-alanyl-L-alanylglycyl-L-isoleucylglycyl-L-isoleucyl-L-leucyl-L-threonyl-L-valine;100: PN: WO2004000351 SEQID: 98 unclaimed sequence;107: PN: WO02069907 SEQID: 107 unclaimed sequence;123: PN: WO2011040978 PAGE: 49 unclaimed sequence;1281: PN: WO2006091734 PAGE: 71 claimed sequence;13: PN: JP2006236151 PAGE: 11 claimed sequence;13: PN: US20040191260 SEQID: 13 unclaimed sequence;13: PN: US20060083735 SEQID: 13 unclaimed sequence;13: PN: WO03047506 SEQID: 13 unclaimed sequence;13: PN: WO2006078059 SEQID: 13 claimed protein;14: PN: WO2020028719 SEQID: 22 claimed protein;16: PN: WO2020172472 SEQID: 160 claimed protein;173: PN: WO0178655 SEQID: 26 claimed sequence;18: PN: WO2010112962 SEQID: 25 unclaimed protein;191: PN: WO2011140284 SEQID: 228 claimed protein;1: PN: US6277956 SEQID: 1 unclaimed sequence;1: PN: WO0116320 SEQID: 1 unclaimed sequence;1: PN: WO2011140595 SEQID: 1 claimed protein;1: PN: WO2017193104 SEQID: 1 claimed protein;21: PN: WO2006120038 SEQID: 21 claimed sequence;21: PN: WO2008042814 SEQID: 20 claimed sequence;22: PN: WO2005037190 TABLE: 2 unclaimed sequence;23: PN: US6710172 SEQID: 24 unclaimed sequence;23: PN: WO2008120202 SEQID: 21 claimed sequence;24: PN: US6531451 SEQID: 24 unclaimed sequence;25: PN: WO2006082391 PAGE: 49 unclaimed sequence;26: PN: WO2011101332 SEQID: 28 claimed protein;273: PN: WO2022190007 SEQID: 273 claimed protein;27: PN: US7001999 SEQID: 27 unclaimed sequence;27: PN: WO0236146 SEQID: 27 claimed sequence;281: PN: WO2012044999 SEQID: 281 claimed sequence;285: PN: WO2019231920 SEQID: 344 claimed protein;2: PN: US20050095655 SEQID: 2 unclaimed sequence;2: PN: WO2012023033 SEQID: 2 claimed protein;2: PN: WO2015110397 SEQID: 2 claimed protein;30: PN: WO0021551 SEQID: 30 claimed sequence;31: PN: WO0050589 SEQID: 31 unclaimed sequence;32: PN: US6291430 SEQID: 68 unclaimed sequence;32: PN: WO0006598 SEQID: 33 unclaimed sequence;33: PN: US6245525 SEQID: 27 unclaimed sequence;34: PN: US20040033541 SEQID: 34 unclaimed sequence;34: PN: WO0020445 SEQID: 24 unclaimed sequence;34: PN: WO0129220 SEQID: 32 unclaimed sequence;34: PN: WO2008097817 SEQID: 34 unclaimed protein;37: PN: WO2005004907 SEQID: 37 unclaimed sequence;3: PN: EP2221060 SEQID: 3 claimed sequence;3: PN: US6326200 SEQID: 1 unclaimed sequence;3: PN: US7268219 SEQID: 3 unclaimed sequence;3: PN: US7723111 SEQID: 3 unclaimed protein;3: PN: WO02072850 SEQID: 3 unclaimed sequence;3: PN: WO2010089064 SEQID: 3 claimed sequence;40: PN: WO2010026165 SEQID: 40 unclaimed protein;41: PN: US20040023314 SEQID: 41 unclaimed sequence;41: PN: WO03100027 SEQID: 41 unclaimed sequence;43: PN: WO0013699 SEQID: 39 unclaimed sequence;4671: PN: WO2010037395 SEQID: 16634 claimed protein;46: PN: FR2842812 SEQID: 46 claimed sequence;47: PN: FR2842811 SEQID: 46 claimed sequence;480: PN: WO2022192524 SEQID: 490 claimed protein;4: PN: WO2011083296 SEQID: 2 unclaimed protein;4: PN: WO2015162204 SEQID: 4 claimed sequence;53: PN: WO0020581 SEQID: 68 unclaimed sequence;54: PN: WO0153833 SEQID: 39 unclaimed sequence;5: PN: WO2011050344 SEQID: 1 unclaimed protein;65: PN: WO0078806 SEQID: 65 unclaimed sequence;66: PN: WO0032785 SEQID: 32 unclaimed sequence;67: PN: US6716809 SEQID: 68 unclaimed sequence;68: PN: WO2004084940 SEQID: 68 unclaimed sequence;69: PN: WO2010143010 SEQID: 69 unclaimed sequence;71: PN: US20220233662 SEQID: 71 claimed protein;72: PN: US20090036653 SEQID: 73 unclaimed protein;75: PN: WO2004085635 SEQID: 78 unclaimed sequence;76: PN: WO2004035085 SEQID: 72 unclaimed sequence;78: PN: WO2012044999 SEQID: 78 unclaimed sequence;87: PN: WO2009051555 SEQID: 92 claimed protein;92: PN: WO2006138562 SEQID: 91 claimed protein;9: PN: WO2005042737 SEQID: 9 unclaimed protein;9: PN: WO2011140255 SEQID: 9 unclaimed protein;PN: WO9953061 SEQID: 27 unclaimed sequence;immunoglobulin, anti-(human MART-1/HLA-A2) (synthetic clone CLA12 L-chain);
分子式：C42H74N10O14
分子量：943.10
CAS號：156251-01-3
純度：HPLC≥98%
沸點：1358.4±65.0 °C | Condition: Press: 760 Torr
密度：1.223±0.06 g/cm3 | Condition: Temp: 20 °C Press: 760 Torr
酸系度數(shù)：3.32±0.10 | Condition: Most Acidic Temp: 25 °C
儲存條件：-20℃，干燥、避光、密封
規(guī)格：5mg10mg20mg50mg100mg500mg1g2g等應(yīng)客戶需求包裝
供應(yīng)單位：四川省維克奇生物科技有限公司
供應(yīng)電話：028-81700200/4008005713
四川省維克奇生物科技有限公司生產(chǎn)中藥類標(biāo)準(zhǔn)品和天然植物有效單體，主打中藥對照品/標(biāo)準(zhǔn)品/天然植物有效單體，化學(xué)合成，抗生素三大板塊。公司推出丹參系列、龍膽系列、蟲草系列等，敬請關(guān)注！ 新批次有現(xiàn)貨，歡迎咨詢。
關(guān)鍵字： 156251-01-3;
成都彼樣生物科技有限公司是四川省成都市一家專業(yè)從事天然藥物純化分離，集生產(chǎn)研發(fā)/銷售于一體的公司。公司名下有四家公司“成都標(biāo)樣生物科技有限公司，成都超九八生物科技有限公司，四川省維克奇生物科技有限公司”。
2014年我公司與中國科學(xué)院成都生物研究所共建聯(lián)合實驗室，主打中藥對照品/標(biāo)準(zhǔn)品/天然植物有效單體，化學(xué)合成，抗生素三大板塊。實驗室擁有一批精密的分離純化系統(tǒng)和檢測設(shè)備;擁有一批技術(shù)精湛的研究隊伍;擁有一套完整的質(zhì)量管理體系;
公司可承接以下業(yè)務(wù)：
1、指定化合物克級---公斤級定制業(yè)務(wù);
2、指定藥材全系列的分離純化業(yè)務(wù);
3、新化合物的分離純化及結(jié)構(gòu)鑒定業(yè)務(wù);
4、指